CorMedix Inc. (CRMD)
NASDAQ$10.47
Market Cap
$635.29M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
378 of 924
Rank in Industry
222 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CRMD Insider Trading Activity
CRMD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $14,985 | 1 | 50 |
Sells | $1,565,670 | 1 | 50 |
Related Transactions
| Mistry Erin | EVP, Chief Commercial Officer | 1 | $14,985 | 0 | $0 | $14,985 |
| Hurlburt Elizabeth | EVP | 0 | $0 | 1 | $1.57M | $-1.57M |
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as …
Insider Activity of CorMedix Inc.
Over the last 12 months, insiders at CorMedix Inc. have bought $14,985 and sold $1.57M worth of CorMedix Inc. stock.
On average, over the past 5 years, insiders at CorMedix Inc. have bought $236,566 and sold $810,532 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mistry Erin (EVP, Chief Commercial Officer) — $14,985.
The last purchase of 1,500 shares for transaction amount of $14,985 was made by Mistry Erin (EVP, Chief Commercial Officer) on 2024‑10‑31.
List of Insider Buy and Sell Transactions, CorMedix Inc.
| 2024-11-14 | Sale | Hurlburt Elizabeth | EVP | 140,027 0.2312% | $11.18 | $1.57M | -6.59% | |
| 2024-10-31 | Mistry Erin | EVP, Chief Commercial Officer | 1,500 0.0026% | $9.99 | $14,985 | +2.34% | ||
| 2024-03-13 | Todisco Joseph | Chief Executive Officer | 13,561 0.024% | $3.74 | $50,718 | +76.54% | ||
| 2023-12-15 | DUNTON ALAN W | director | 3,000 0.0055% | $3.30 | $9,900 | +52.11% | ||
| 2023-12-14 | DUNTON ALAN W | director | 3,000 0.0055% | $3.45 | $10,350 | +45.51% | ||
| 2023-11-17 | Mistry Erin | Chief Commercial Officer | 1,000 0.0018% | $4.00 | $4,000 | +17.46% | ||
| 2023-09-08 | Todisco Joseph | Chief Executive Officer | 10,000 0.0183% | $3.71 | $37,100 | +4.05% | ||
| 2023-05-18 | Kaplan Myron | director | 6,000 0.0139% | $4.54 | $27,258 | -14.19% | ||
| 2023-05-17 | Todisco Joseph | Chief Executive Officer | 5,000 0.0119% | $4.58 | $22,900 | -12.90% | ||
| 2023-05-17 | Stewart Robert A | director | 10,000 0.0227% | $4.37 | $43,735 | -12.90% | ||
| 2023-05-17 | Costa Paulo F | director | 10,000 0.0241% | $4.65 | $46,500 | -12.90% | ||
| 2023-05-17 | DUNTON ALAN W | director | 3,000 0.0067% | $4.33 | $12,980 | -12.90% | ||
| 2022-11-15 | Todisco Joseph | Chief Executive Officer | 20,000 0.0514% | $3.82 | $76,400 | +11.65% | ||
| 2022-08-24 | Todisco Joseph | Chief Executive Officer | 4,700 0.0114% | $3.92 | $18,424 | +4.58% | ||
| 2022-05-17 | Kaplan Myron | 5,000 0.0124% | $3.78 | $18,900 | +3.40% | |||
| 2022-05-16 | Todisco Joseph | Chief Executive Officer | 10,000 0.0235% | $3.38 | $33,800 | +8.86% | ||
| 2021-12-06 | David Matthew T | Interim CEO and CFO | 2,000 0.0052% | $4.50 | $9,000 | -13.93% | ||
| 2021-11-17 | David Matthew T | Interim CEO and CFO | 1,000 0.0027% | $5.07 | $5,070 | -20.71% | ||
| 2021-11-16 | Kaplan Myron | director | 10,000 0.0262% | $5.14 | $51,400 | -22.60% | ||
| 2021-05-21 | Sale | Masson-Hurlburt Elizabeth | EVP, Head of Clinical Ops | 8,000 0.0212% | $6.92 | $55,394 | -28.17% |
Total: 167
*Gray background shows transactions not older than one year
Insider Historical Profitability
13.42%
| Mistry Erin | EVP, Chief Commercial Officer | 52011 0.0857% | $544,555.17 | 2 | 0 | +17.46% |
| Gelbfish Gary A. | director | 2101121 3.4628% | $22M | 2 | 0 | <0.0001% |
| Todisco Joseph | Chief Executive Officer | 352839 0.5815% | $3.69M | 6 | 0 | +16.79% |
| TELLEZ CORA M | director | 182371 0.3006% | $1.91M | 15 | 0 | <0.0001% |
| Khan Mehmood | director | 178767 0.2946% | $1.87M | 10 | 0 | +14.81% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
CorMedix Inc. (CRMD) | $3,596,906 | 112 | 13.42% | $635.29M |
$36,510,315 | 95 | 8.95% | $609.56M | |
$7,929,017 | 58 | 21.56% | $787.18M | |
$678,065,999 | 37 | -13.32% | $603.22M | |
$94,912,877 | 34 | -7.15% | $626.42M |
CRMD Institutional Investors: Active Positions
| Increased Positions | 87 | +95.6% | 7M | +36.56% |
| Decreased Positions | 37 | -40.66% | 3M | -16.06% |
| New Positions | 40 | New | 2M | New |
| Sold Out Positions | 12 | Sold Out | 2M | Sold Out |
| Total Postitions | 141 | +54.95% | 23M | +20.5% |
CRMD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $47,323.00 | 7.49% | 4.57M | +911,603 | +24.93% | 2024-12-31 |
| Vanguard Group Inc | $34,998.00 | 5.54% | 3.38M | +309,514 | +10.09% | 2024-12-31 |
| Elliott Investment Management L.P. | $29,740.00 | 4.71% | 2.87M | +1M | +85.14% | 2024-12-31 |
| State Street Corp | $15,055.00 | 2.38% | 1.45M | +227,392 | +18.55% | 2024-12-31 |
| Geode Capital Management, Llc | $14,430.00 | 2.28% | 1.39M | +108,356 | +8.44% | 2024-12-31 |
| First Turn Management, Llc | $10,582.00 | 1.67% | 1.02M | +1M | New | 2024-12-31 |
| Northern Trust Corp | $5,300.00 | 0.84% | 511,565 | +64,243 | +14.36% | 2024-12-31 |
| J. Goldman & Co Lp | $4,738.00 | 0.75% | 457,320 | +314,880 | +221.06% | 2024-12-31 |
| D. E. Shaw & Co., Inc. | $4,625.00 | 0.73% | 446,414 | +125,425 | +39.08% | 2024-12-31 |
| Morgan Stanley | $4,132.00 | 0.65% | 398,849 | +56,463 | +16.49% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.